Why Moderna (MRNA) fell 1.51%
Moderna (MRNA) fell 1.51% on September 30, 2026 — Patent loss in Bayer vaccine case hits biotech.
What happened
A federal court refused to dismiss Bayer's patent infringement case against Pfizer, BioNTech, and Moderna over mRNA vaccine technology, allowing the lawsuit to proceed to trial.
Why it moved
The denial of a motion to dismiss keeps material royalty and damages risk alive in Moderna's mRNA vaccine economics; the company now faces trial exposure that could require licensing payments or impose product…
Why it matters
Within Healthcare & Biotech, the ruling underscores IP risk in the mRNA space — a foundational asset class for both Moderna and the sector; if Bayer wins, it creates a precedent and cost structure that could ripple…
What would break the thesis
If the court later narrows Bayer's claims, finds non-infringement, or the parties settle on immaterial terms, the risk dissolves; also monitor trial timeline — a long litigation runway keeps uncertainty elevated and…